Alzheimer's disease

Roche pays Ionis $60M upfront to license RNA-targeting Alzheimer's, Huntington's programs
Roche pays Ionis $60M upfront to license RNA-targeting Alzheimer's, Huntington's programs
Fierce Biotech
Roche
Ionis Pharmaceuticals
RNA
Alzheimer's disease
Huntington's disease
Flag link:
Japan approves Alzheimer's treatment Leqembi by Eisai and Biogen
Japan approves Alzheimer's treatment Leqembi by Eisai and Biogen
Reuters
Biogen
Eisai
Japan
Leqembi
Alzheimer's disease
Flag link:
Cassava Sciences Announces Positive Interim Safety Review of Simufilam On-going Phase 3 Trials in Patients with Alzheimer’s Disease
Cassava Sciences Announces Positive Interim Safety Review of Simufilam On-going Phase 3 Trials in Patients with Alzheimer’s Disease
BioSpace
Cassava Sciences
clinical trials
Simulfilam
Alzheimer's disease
Flag link:
Anavex’s Blarcamesine Slows Cognitive Decline in Alzheimer’s Patients
Anavex’s Blarcamesine Slows Cognitive Decline in Alzheimer’s Patients
BioSpace
Anavex
Alzheimer's disease
blarcamesine
clinical trials
Flag link:
The Alzheimer’s Treatment Landscape: Leqembi vs. Donanemab
The Alzheimer’s Treatment Landscape: Leqembi vs. Donanemab
BioSpace
Alzheimer's disease
Eli Lilly
Biogen
Eisai
Leqembi
donanemab
Flag link:
Competing in These 3 Markets Could Send Eli Lilly Stock Soaring
Competing in These 3 Markets Could Send Eli Lilly Stock Soaring
Motley Fool
Eli Lilly
Alzheimer's disease
obesity
painkillers
Flag link:
Vaxxinity Alzheimer’s treatment shows promising results in early trial
Vaxxinity Alzheimer’s treatment shows promising results in early trial
Biopharma Reporter
Vaxxinity
clinical trials
UB-311
Alzheimer's disease
Flag link:
New Alzheimer’s drug raises hopes — along with questions
New Alzheimer’s drug raises hopes — along with questions
Medical Marketing and Media
FDA
Alzheimer's disease
Eisai
Biogen
Leqembi
Flag link:
More Alzheimer's Treatments Are Coming: This Company Can Help With Early Detection
More Alzheimer's Treatments Are Coming: This Company Can Help With Early Detection
Motley Fool
Alzheimer's disease
diagnostics
Quest Diagnostics
Flag link:
Takeda, Denali drop Alzheimer's asset after phase 1 peak reveals 'narrow therapeutic window'
Takeda, Denali drop Alzheimer's asset after phase 1 peak reveals 'narrow therapeutic window'
Fierce Biotech
Takeda
Denali Therapeutics
Alzheimer's disease
clinical trials
Flag link:
The real costs of the new Alzheimer’s drug, most of which will fall to taxpayers
The real costs of the new Alzheimer’s drug, most of which will fall to taxpayers
Medical Marketing and Media
Eisai
Biogen
Leqembi
Alzheimer's disease
Flag link:
Headband to treat mild and moderate Alzheimer’s disease to be trialled
Headband to treat mild and moderate Alzheimer’s disease to be trialled
Clinical Trials Arena
Alzheimer's disease
Medtech
clinical trials
Electro Cellular Healthcare Solutions
Flag link:
Promising new Alzheimer's drugs may benefit whites more than Blacks
Promising new Alzheimer's drugs may benefit whites more than Blacks
Reuters
Alzheimer's disease
racial disparity
Flag link:
After quitting FDA adcomm in protest of Aduhelm decision, Harvard's Aaron Kesselheim finds agency has an approval bias
After quitting FDA adcomm in protest of Aduhelm decision, Harvard's Aaron Kesselheim finds agency has an approval bias
Fierce Pharma
FDA
Biogen
Aduhelm
Alzheimer's disease
advisory committees
drug approvals
Flag link:
I Was Concerned About Biogen Until I Heard These 11 Words From Its CEO
I Was Concerned About Biogen Until I Heard These 11 Words From Its CEO
Motley Fool
Biogen
Alzheimer's disease
Pharma CEOs
Chris Viehbacher
Flag link:
Companies to Watch: 12 Late-Stage Contenders in Neurodegenerative Disease
Companies to Watch: 12 Late-Stage Contenders in Neurodegenerative Disease
BioSpace
neurodegenerative disease
Alzheimer's disease
Axsome Therapeutics
Eli Lilly
Anavex
TauRx
AB Science
ALS
BrainStorm Cell Therapeutics
Seelos Therapeutics
Parkinson's Disease
AbbVie
Mitsubishi Tanabe Pharma
Annovis
Huntington's disease
Prilenia Therapeutics
Neurocrine
Flag link:
After winning full FDA nod for Leqembi, Eisai touts 'promising' study on subcutaneous version
After winning full FDA nod for Leqembi, Eisai touts 'promising' study on subcutaneous version
Fierce Pharma
Eisai
Biogen
Leqembi
FDA
Alzheimer's disease
subcutaneous drug delivery
Flag link:
Lilly’s donanemab flaunts strong clinical profile, ready to compete with Leqembi
Lilly’s donanemab flaunts strong clinical profile, ready to compete with Leqembi
Clinical Trials Arena
Eli Lilly
donanemab
Eisai
Biogen
Leqembi
Alzheimer's disease
Flag link:
AAIC 2023 – Acumen’s new amyloid approach impresses
AAIC 2023 – Acumen’s new amyloid approach impresses
EP Vantage
AAIC
Acumen
Alzheimer's disease
ACU193
Flag link:
AAIC: First Clinical Data from an RNAi Therapeutic for Alzheimer’s Continue to Impress
AAIC: First Clinical Data from an RNAi Therapeutic for Alzheimer’s Continue to Impress
BioSpace
AAIC
Alnylam
RNAi
Alzheimer's disease
ALN-APP
clinical trials
Flag link:

Pages